Allergen-specific Immunoglobulin G and Fc gamma receptor complex

Allergen-specific IgG, particularly the IgG4 subclass, is a critical component of the immune system's regulatory response to allergens. These antibodies circulate in the blood and bind to Fc gamma receptors (FcγRs) on effector cells such as mast cells and basophils [1]. In the context of allergic disease, they function as "blocking antibodies" by competing with IgE for allergen binding, thereby preventing the cross-linking of high-affinity IgE receptors (FcεRI) that leads to degranulation [2]. Additionally, IgG-allergen complexes can engage the inhibitory receptor FcγRIIb, which recruits phosphatases like SHIP-1 to dampen activating signals within the cell [3]. This dual mechanism of competitive inhibition and active signaling suppression is the primary goal of allergen immunotherapy (AIT) [4]. Therapeutic agents like sublingual or subcutaneous allergen extracts are designed to shift the immune response from a Th2-driven IgE production toward a regulatory response characterized by increased allergen-specific IgG4 [5]. Monitoring these IgG levels serves as a key biomarker for clinical efficacy and the development of long-term tolerance in patients with respiratory, food, or venom allergies [1][2].

Other names

Blocking antibodiesAllergen-specific IgG4Fc gamma receptorsIgG-FcγRIIb inhibitory axis

Induction of allergen-specific IgG (primarily IgG4) which acts as a blocking antibody to neutralize allergens and co-aggregates the inhibitory FcγRIIb with the activating FcεRI to suppress mast cell and basophil degranulation [1][2][4].